左卡尼汀治疗缺血性心脏病心力衰竭的临床疗效分析

Clinical Analysis of Levocarnitine in Treatment of Ischemic Heart Disease Heart Failure

目的:探讨左卡尼汀治疗缺血性心脏病心力衰竭患者的临床疗效。方法:选择我院收治的116例缺血性心脏病合并心力衰竭患者的临床资料,其中,观察组58例例患者采用左卡尼汀进行治疗,对照组58例患者采用曲美他嗪进行治疗,比较两组患者的临床疗效。结果:治疗2个月后,观察组患者的总有效率为91.38%,明显高于对照组患者,且差异具有明显统计学意义(P<0.05),同时,两组患者治疗后的LVEF、FS较治疗前得到了较为明显的改善,且组内差异具有明显统计学意义(P<0.05)。结论:采用左卡尼汀治疗缺血性心脏病心力衰竭具有十分显著的疗效,有利于促进患者早期恢复,值得临床广泛推广和应用。

Objective：To investigate clinical efficacy of levocarnitine for the treatment of ischemic heart disease in patients with heart failure. Methods：116 patients with ischemic heart disease were divided into two groups, including observed group of 58 patients with levocarnitine treatment and control group of 58 patients with trimetazidine treatment. Results：After 2 months of treatment, the observation group patients total effective rate was 91.38%, significantly higher than control group, and the difference was statistically significant （P〈0.05）, after the two groups of patients with LVEF, FS has been a more significant improvement than before treatment, and group differences statistically was significant （P〈0.05）. Conclusion：Levocarnitine in treatment of ischemic heart disease heart failure has a very significant effect, which is conducive to promoting early recovery in patients, and it is worth the clinical widely promoted and applied.